People are absolute garbage at thinking about scale.
It kills less than that in the demographic in question, not to mention that is only of those who contract the virus.
> People are absolute garbage at thinking about scale.
I don’t think it is that, I think it is that for better or worse humans tend to view wrongs through inaction as less atrocious than wrongs through action. Additionally - they already have better alternatives and plenty of supply in the US (Moderna and Pfizer vaccines) so they are opting to just use those at the moment.
Second, there’s evidence that even if people don’t die, there can be long term neurological effects [2].
Third, even if we accept your number, 1 in 200 would still be 1.5 million Americans dead, not even considering the rest of the world. I am personally not comfortable doing nothing to stop that number.
I agree that being super worried about a 1 in a million blood clot might be short sighted, especially since the death rate from catching the virus is 2 in 100.
People with asymptomatic infections (which are the majority of them) do not have any reason to get tested, so they do not count as "cases".
As I said, that still implies that if everyone in the United States got it, 1.5 million of them would die (320,000,000 * .005). That's a lot of people.
If a government did nothing to prevent a terrorist attack that killed 1.5 million people, most people would (rightly) be pretty upset.
EDIT: Also, forgot to mention, it's totally disingenuous to only look at "deaths". We do not fully know the long term health effects, but as I stated there's potential neurological effects, potential risks of type 1 diabetes, and people permanently losing smell.
You have 100M infected in US as the estimate. A 2% death rate is 2M deaths from COVID alone. I've not seen anything like that as credible death rates - it's at least half if not a quarter of this rate - more like 0.5% or less. Do the same thing in countries with 70% infected rates - if fatality was really 2%+ death counts would be insane.
You really start to understand how people start to doubt the crap COVID "experts" put out when basic math shows it is garbage.
Johns Hopkins University. I don't feel like that's typically considered a bad source. Maybe it's a bit high or they're looking at different data sets.
But again, and I cannot overstate this enough, even if I accept the 0.5% number, that's still a lot of deaths, about 1.5 million if everyone in the US gets it.
According to the NYTimes [1], there's been about half a million deaths from COVID. If your provided number of 100M infected people is correct, then that would be consistent with 1.5M dying if everyone gets infected (US population ~= 3 * 100M, 3 * 500,000 = 1.5M).
[1] https://www.nytimes.com/interactive/2020/us/coronavirus-us-c...
If they follow your line of thinking and it's all fine... no-one's going to be writing articles praising them.
If they follow your line of thinking and more people die form blood clots... people will write articles attacking them. Questions will be asked, and careers may be harmed. Etc.
Not really. 1 in 200 is fewer than how many die a year anyway of all causes.
Surprisingly, even the elderly and sick people often do not understand the risks.
We want if there are safer options. Not all vaccines are equal. Important question is why we unable to scale up production of mRNA vaccines?
Where are you getting the idea that we can't?
Hundreds of millions of doses of the Pfizer and Moderna vaccines have already been made. Pfizer expects to make 2 billion doses this year.
https://www.novartis.com/news/media-releases/novartis-signs-...
> Novartis announced today that it has signed an initial agreement to leverage its manufacturing capacity and capabilities in order to address the COVID-19 pandemic by supporting the production of the Pfizer-BioNTech COVID-19 Vaccine. The agreement will see Novartis utilizing its aseptic manufacturing facilities at its site in Stein, Switzerland.
https://www.merck.com/stories/why-were-excited-to-partner-on...
> On March 2, we announced a partnership with Johnson & Johnson to expand manufacturing capacity and supply of its COVID-19 vaccine. Under the Biomedical Advanced Research and Development Authority (BARDA) agreement, our company is adapting and making available some of our existing manufacturing sites to accelerate manufacturing efforts for the vaccine and enable more timely delivery and administration.
https://investors.modernatx.com/news-releases/news-release-d...
> Under the terms of the agreement, the companies plan to establish manufacturing suites at Lonza’s facilities in the United States and Switzerland for the manufacture of mRNA-1273 at both sites. Technology transfer is expected to begin in June 2020, and the companies intend to manufacture the first batches of mRNA-1273 at Lonza U.S. in July 2020.
https://www.astrazeneca.com/media-centre/press-releases/2021...
> AstraZeneca and IDT Biologika also intend to strengthen Europe’s vaccine manufacturing capability with a joint investment to build large additional drug substance capacity for the future. Details of the agreement are to be finalised. Both companies plan to invest in capacity expansion at IDT Biologika’s production site in Dessau, Germany to build up to five 2,000-litre bioreactors capable of making tens of millions of doses per month of AstraZeneca’s COVID-19 vaccine. The new assets are estimated to be operational by the end of 2022.
1. https://theconversation.com/how-patent-laws-get-in-the-way-o...
2. https://www.thedailybeast.com/heres-why-it-will-be-hard-to-r...